Search for: "United States v. Georgia-Pacific Corp." Results 61 - 73 of 73
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
28 Mar 2008, 6:00 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included:Forbes interview with M Meurer (co author of ‘Patent Failure’): (Patent Prospector), (IPBiz), (IPBiz), (IPBiz), (IAM), (Technological Innovation and Intellectual Property), (Patent Prospector),Rambus – Rambus stock soars following jury’s dismissal of antitrust and fraud charges from Hynix, Micron, and Nanya that… [read post]
7 Feb 2008, 10:46 am
"[A]ll such proceedings for the enforcement, or to restrain violations, of this chapter shall be by and in the name of the United States. [read post]
22 Nov 2010, 2:16 am by Kelly
Kappos (IP Spotlight) (Patent Docs) Sham patent reexamination action not available in State Court says CAFC: Lockwood v. [read post]
24 May 2010, 10:49 pm
(IP finance) Withdrawing patent applications – a matter of priority (IPKat)   United States US General U.S. [read post]
6 Dec 2010, 2:36 am by Kelly
Maersk Contractrors USA, Inc (IP Law Blog) US Patents – Lawsuits and strategic steps Columbia University’s School for Engineering and Applied Science – Columbia’s patented smart grid technology to power FedEx’s NYC EV Fleet (Green Patent Blog) Georgia-Pacific Consumer Products – ALJ Gildea grants motion to terminate investigation in Certain Electronic Paper Towel Dispensing Devices (337-TA-718) based on consent order (ITC Law Blog) GS Cleantech… [read post]
31 Jan 2010, 7:16 pm by admin
“The United States brought this case to protect an important body of water, Pyramid Lake,” said Ignacia S. [read post]
22 Mar 2008, 2:00 am
: (IPBiz),US: Two remaining challenged WARF embryonic stem cell patents upheld in ex parte reexamination: (Holman's Biotech IP Blog), Pharma & Biotech - ProductsAricept (Donepezil) – USV wins appeal against USPTO decision: (Spicy IP),Celerex (Celecoxib) – CAFC decision in Celebrex patents dispute between Pfizer and Teva will cut patent term by one and a half years: (Patent Baristas), Inersan – Ranbaxy in-licenses Inersan to CD Pharma to market in India and… [read post]